15.Bruno B A, Antonio R F, Sebastiaoet al.,(2010).SeverePlasmodium vivax malaria exhibits marked inflamatory imbalance.Malaria Journal2010, 9:13.

16.Yan Bi, Weiwei Yu, Wenbiao Hu, Hualiang Lin (2013). Impact of climate variability o­n Plasmodium vivax and Plasmodium falciparummalaria in Yunnan province, China. Parasites & Vectors 2013, 6:357

17.CDC (2015). Manual for quantification of malaria commodities.Rapid diagnostic tests and artemisinin-based combination therapy for first line treatment ofPlasmodium falciparummalaria.

18.Chen N,Auliff A,Rieckmann K,Gatton M,Cheng Q et al.,(2007).Relapse ofPlasmodium vivaxinfection result from clonal hypnozoites activated at predeterminated intervals.Journal of infectious diseases,195:934-941.

19.Chotivanich K,Udomsangpetch R,McGready R,Proux Set al.,(2002). Central role of the spleen in malaria parasite clearance.J. Infect Dis;185(10):1538-41.

20.Clarissa M. Moreira, Mahmoud Abo?Shehada, Ric N. Price (2015). A systematic review of sub?microscopicPlasmodium vivaxinfection.Malar J(2015) 14:360.

21.David G. Lalloo, Delane Shingadia, David J. Bellet al., (2016). UK malaria treatment guidelines 2016.Journal of Infection2016;72; 635-649.

22.Dhanpat K. Kochar, Vishal Saxena, Narvachan Singh et al.,(2005).Plasmodium vivaxmalaria.Emerging Infectious Diseases,vol.11, No.1.

23.Djimde A, Doumbo OK, Cortese JF,et al.(2001).A molecular marker for chloroquine-resistant falciparum malaria.N. Engl J Med;344:257-263.

24.Nicholas M Douglas, Nicholas M Anstey, Pierre A Buffet (2012).The anaemia ofPlasmodium vivaxmalaria.Malaria Journal, 2012, :135

25.ECDC (2012).Rapid risk assessment autochthonousPlasmodium vivaxmalaria in Greece.European Centre for Disease Prevention andControl, Stockholm.

26.Fabio T.M. Costa, Stefanie C.P. Lopes, Letusa Albrecht (2012).On the pathogenesis of Plasmodium vivax malaria: Perspectives from the Brazilian field.J. Parasitol.(2012), doi.org/10.1016/j.ijpara.2012.08.007

27.Fernando Fonseca Val, Vanderson Souza Sampaio, Maria Belén Cassera et al., (2014).Plasmodium vivaxmalaria elimination: should innovative ideas from the past be revisited?Mem Inst Oswaldo Cruz,Rio de Janeiro, Vol.109(5): 522-524.

28.FontouraPS, Finco BF, Lima NF, de Carvalho JF, Jr., Vinetz JMet al.,(2016). Reactive case detection forPlasmodium vivaxmalaria elimination in rural Amazonia.PloS Negl Trop Dis10(12): e0005221. doi:10.1371

29.Fryauff DJ, Tuti S, Mardi Aet al.,(2004). Chloroquine resistantPlasmodium vivaxin transmigration settlement of west Kalimantan, Indonesia.Am J Trop Med Hyg;59 (4):513-8.

30.Gething PW, Elyazar IRF, Moyes CL, Smith DL, Battle KEet al., (2012). A long neglected world malaria map:Plasmodium vivaxendemicity in 2010.PloS Negl Trop Dis6(9):e1814.

31.Giao PT, Binh TQ, Peter VJ, HungLQ, Nam NVet al.,(2002).Artemisinins or chloroquine for blood stagePlasmodium vivaxmalaria in Vietnam.Tropical Medicine and International health, 2002, 7:856-864

32.Gogtay NJ, Desai S, Kadam VSet al.,(2000).Relapse pattern ofPlasmodium vivaxin Mumbai: A study of 283 cases of vivax malaria.J. Assoc Physicician India;48(11):1085-6.

33.Goller JL,Jolley D,Ringwald P,Biggs BA(2007).Regional differences in the response ofPlasmodium vivaxmalaria to primaquin as anti-relapse therapy.American Journal of Tropical medicine and Hygiene,76:203-207.

34.Ghulam Rahim Awab, Sasithon Pukrittayakameeet al.,(2010).Dihydroartemisinin - piperaquine versus chloroquine to treat vivax malaria in Afghanistan: An open randomized, non-inferiority, trial.Malaria Journal9:105.

35.Guthmann JP,Pittet A,Lesage A,Imwong M,Nosten Fet al.,(2008).Plasmodium vivaxresistance to chloroquin in Dawei, Southern Myanmar.Trop Med Int Health.2008;13(1):91-8.  

36.Hai-Mo Shen, Shen-Bo Chen, Yue Wang, Jun-Hu Chen (2015). Whole genome sequencing of aPlasmodium vivaxisolate from the China-Myanmar border area.Mem Inst Oswaldo Cruz,Rio de Janeiro, Vol.110(6): 814-816.

37.Hampâté Ba, Craig W. Duffy, Ambroise D. Ahouidi (2016).Widespread distribution ofPlasmodium vivaxmalaria in Mauritania o­n the interfaceof the Maghreb and West Africa.Malaria Journal2016;15:80

38.Imwong M, Snounou G, Nurhayatiet al.(2007).Plasmodium vivaxinfection usually result from activation of heterologous hypnozoites.Journal of Infectious Diseases,195:927-933.

39.Jan Peter Verhaveet al.,(2013). Experimental, therapeutic and natural transmission of Plasmodium vivax tertian malaria: scientific and anecdotal data o­n the history of Dutch malaria studies.Parasites & Vectors2013, 6:19

40.Jean Francois Faucher, Anne Pauling Bellanger, Catherine Chirouzeet al., (2015).Primaquine for radical cure ofPlasmodium vivaxandPlasmodium ovalemalaria: An observational survey (2008-2010).International Society of Travel Medicine2013; Volume 20 (Issue 2): 134-136

41.Jean Popovici, Didier Ménardet al.,(2015).Challenges in antimalarial drug treatment for vivax malaria control.Trends in Molecular Medicine, 2015, Vol. 21, No.12: 1-13

42.Jetsumon Sattabongkot, Takafumi Tsuboi, Gabriela E. Zollneret al.,(2004).Plasmodium vivaxtransmission: Chances for control?TRENDS in Parasitology, vol.20 No.4 April 2004

43.John Barnwell, Jane Carlton, William Collins (2007). Neglected burden of human vivax malaria: Comparative analysis ofPlasmodium vivaxand key related species.Plasmodium comparative genomics writing group

44.Katherine E Battle, Markku S Karhunen, Samir Bhattet al., (2014). Geographical variation inPlasmodium vivaxrelapse.Malaria Journal2014, 13:144.

45.Katherine E. Battle, Peter W. Gething, Iqbal R.F. Elyazar (2012). The Global Public Health Significance ofPlasmodium vivax.Advances in Parasitology, Vol.80, ISSN 0065-308X, dx.doi.org/10.1016/B978-0-12-397900-1.00001-3

46.Katherine E. Battle, Carlos A. Guerra, Nick Goldinget al.,(2015).Global database of matchedPlasmodium falciparumandP. vivaxincidence and prevalence records from 1985-2013. www.nature.com/data/ 2:150012, doi: 10.1038/sdata.2015.12

47.Kanchana Rungsihirunrat, Poonuch Muhamad, Wanna Chaijaroenkulet al., (2015).Plasmodium vivaxdrug resistance genes;Pvmdr1andPvcrt-oPolymorphisms in relation to chloroquin sensitivity from a malaria endemic area of Thailand.Korean J ParasitolVol. 53, No.1: 43-49.

48.Ketema Tsige,Ketema Bacha,Tarekegn Birhanuet al.,(2009).Chloroquin-resistantPlasmodium vivaxmalaria in Serbo town, Jimma zone, south-west Ethiopia.Malaria journal; 8:177.

49.Khojasteh Sharifi-Sarasiabi, Ali Haghighi, Bahram Kazemiet al., (2016). Molecular surveillance ofPlasmodium vivaxandPlasmodium falciparum dhfrmutations in isolates from southern Iran.Rev. Inst. Med. Trop. Sao Paulo,2016;58:16

50.Kitchener S, Nasveld P, Edstein MDet al.,(2007).Tafenoquine for the treatment of recurrentPlasmodium vivaxmalaria.Am J Trop Med Hyg,2007:76 (3):494-6

51.Kurcer MA, Simek Z, Kurcer Zet al.,(2006).The decreasing efficacy of chloroquin in the treatment ofPlasmodium vivaxmalaria, in Sanliurfa, south-eastern Turkey.Ann Trop Med Parasitol,2006;100(2):109-13.

52.KStepniewska,Ashley E,Lee SJ,Anstey N,Barnes KI,Binh TQ,D'Alessandro U(2010).In vivoparasitilogical measures of artemisinine susceptibility.J Infect Dis.15;201(4):570-9.

53.Laurent Brutus, José Santalla, Dominique Schneider (2013).Plasmodium vivaxmalaria during pregnancy, Bolivia.Emerging Infectious Diseases,vol. 19, No. 10, October 2013

54.Lee KS, Kim TH, Kim ESet al., (2009).Short report: chloroquin resistantPlamodium vivaxmalaria in the Republic of Korea.Am J Trop Hyg,80(2):215-7.

55.Leeha Singh, Surbhi Rathi, Santosh Kondekar et al.,(2016).Per protocol analysis of therapeutic efficacy of chloroquine for the treatment ofPlasmodium vivaxmalaria in children.International journal contemporary paediatrics. http://dx.doi.org/10.18203/2349-3291.ijcp20161909

56.Lígia Antunes Gonçalves, Pedro Cravo, Marcelo Urbano Ferreira (2014).EmergingPlasmodium vivaxresistance to chloroquine in South America: an overview.Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol.109 (5): 534-539.

57.Lili Yuan, Ying Wang, Daniel M. Parker, Bhavna Guptaet al.,(2015).Therapeutic responses ofPlasmodium vivaxmalaria to chloroquinand primaquine treatment in Northeastern Myanmar.Antimicrob Agents Chemother59:1230-1235.

58.Lemu Golassa, Berhanu Erko, Frederick N Baliraine, Abraham Aseffa (2015).Polymorphisms in chloroquin resistance-associated genes inPlasmodium vivaxin Ethiopia.Malaria Journal(2015) 14:164.

59.Luciano Rodrigues Simões,Eduardo Rodrigues Alves-Jr, Daniele Ribatski-Silva (2010).Factors associated with recurrentPlasmodium vivaxmalaria in Porto Velho, Rondônia State, Brazil, 2009.Cad. Saúde Pública, Rio de Janeiro, 30(7):1403-1417, jul, 2014

60.Márcia A. Alexandre, Cynthia O. Ferreira, André M. Siqueira. SeverePlasmodium vivaxmalaria, Brazilian Amazon.Emerging Infectious Diseases, vol.16, No.10:1611-1614

61.Mohamed H. Abdelraheem, Musab M. A. Albsheer, Hiba S. Mohamed (2016). Transmission ofPlasmodium vivaxin Duffy-negative individuals in central Sudan.Trans R Soc Trop Med Hyg; 110:258-260, doi:10.1093/trstmh/trw014

62.Mohapatra MK, Padhiary KN, Mishra DPet al., (2002).Atypical manifestations ofPlasmodium vivaxmalaria.Indian J Malariol;39(1-2):18-25.

63.Mueller I,Galinski MR,Baird JK,Carlton JMet al.(2009).Key gaps in the knowledge ofPlasmodium vivax, a neglected human parasite.Lancet Infect Dis 2009; 9(9): 555-66.

64.Nacher M, Silachamroon U, Singhavisanon P(2004).Risk factors forPlasmodium vivaxgametocyte carriage in Thailand.Am J Trop Med,2004;71(6):693-5.

65.Nandy A, Addy M, Maji AKet al.,(2003).Monitoring the chloroquine sensitivity ofPlasmodium vivaxfrom Calcutta and Orissa, India.Ann Trop Parasitol; 97 (3):215-20

66.Nasveld P, Kitchner Set al.,(2005).Treatment of acute vivax malaria with tafenoquine?.Trans R Soc Trop Med Hyg,2005; 99(1):2-5

67.Orjuela-Sanchez P, Da Silva NS, da Silva-Nune Met al.,(2009).Recurrent parasitemia and population dynamics ofPlasmodium vivaxpolymorphisms in rural Amazonia.Am J Trop Med and Hyg; 81(6):961-8.

68.Park JW,Jun G,Yeom JS et al.,(2009).Plasmodium vivaxmalaria: Status in the republic of Korea following reemergence.Korean J Parasitol;47 Suppl:S39-50.

69.Price RN, Tjitra E, Guerra CAet al.,(2007).Vivax malaria: Negleted and not benign.Am J Trop Med Hyg;77(6 suppl):79 - 87.

70.Price RN, Douglas NM, Anstey NMet al.,(2009). New developments inPlasmodium vivaxmalaria: severe disease and the rise of chloroquin resistance.Curr Opin Infect Dis; 22(5); 430-5.

71.Purva Gupta,Rajni Sharma, Jagdish Chandra, Vineeta Singh (2016). Severe malaria due toPlasmodium vivax:Case report.Curr pediatr res2016; 20 (1&2): 24-28.

72.Ric N Price, Lorenz von Seidlein, Neena Valecha, Francois Nosten, J Kevin Bairdet al.,(2014).Global extent of chloroquine-resistantPlasmodium vivax: A systematic review and meta-analysis.Lancet Infect Dis2014;14:982-91.

73.Rosalind E. Howes, Katherine E. Battle, Kamini N. Mendiset al.,(2013). Global epidemiology ofPlasmodium vivax. Published o­nline July 11, 2016; doi:10.4269/ajtmh.16-0141.

74.Rosalind E., Howes Katherine E., Battle Nick Golding, Simon I. Hay (2015).Plasmodium vivaxthematic review epidemiology.Malaria Atlas project, Oxford university

75.Roy M, Bouma MJ, Ionides EL, Dhiman RC, Pascual M (2016). The Potential elimination ofPlasmodium vivaxmalaria by relapse treatment: Insights from atransmission model and surveillance data from NW India.PLoS Negl Trop Dis7(1): e1979.

76.Rowena E. Martinet al.,(2004).The malariaparasite's chloroquineresistance transporter is a member of the drug/ metabolite transporter superfamily.Molecular BiologyandEvolution2004 21(10):1938-49.

77.Rupam Tripura, Thomas J. Peto, Jeremy Chalk, Sue J. Lee (2016). PersistentPlasmodium falciparumandPlasmodium vivaxinfections in a western Cambodian population: implications for prevention, treatment and elimination strategies.Malar J(2016) 15:181.

78.Ruth O. Payne, Paul M. Griffin, James S. McCarthy, Simon J. Draper (2017).Plasmodium vivaxcontrolled human malaria infection: Progress and Prospects.Trends in Parasitology, February 2017, Vol.33, No. 2.

79.Sharrock WW, Suwannarusk R, Lek-Uthai Uet al.,(2008).Plasmodium vivaxtrophozoites insensitive to chloroquin.Malarial journal27;7:94.

80.Soto J, Toledo J, Gutierrez Pet al., (2001).Plasmodium vivaxclinically resistant to chloroquin in Colombia.Am J Trop Hyg Aug;65(2):90-3.

81.Stano I, Suprijanto S, Nurhayatiet al.,(2009).Resistance to chloroquin byPlasmodium vivaxat Alor in the Lessser Sundas archipelago in eastern Indonesia.Am J Trop Med Hyg,2009 Aug;81(2):338-42.

82.Hiwot Teka,Beyene Petros,Lawrence Yamuahet al.,(2008).Chloroquin-resistantPlasmodium vivaxmalaria in Debre Zeit, Ethiopia.Malaria journal,2008 Oct 29; 7-220.

83.Pham Vinh Thanh, Hong Nguyen Van, Nguyen Van Van, Melva Louisa,Kevin Baird et al., (2015).ConfirmedPlasmodium vivaxresistance to chloroquin in Central Vietnam. Antimicrob. Agents Chemother.doi:10.1128/AAC.00791-15

84.Tjitra E, Anstey NM, Sugiarto P et al.(2008). Multidrug-resistantPlasmodium vivaxassociated with severe and fetal malaria: A prospective study in Papua, Indonesia.Pls Med,2008 Jun 17; 5(6):128.

85.Toi Van Pham, Phuong Pham Nguyen, Tho Nguyen Duc Khanh, Nhien Nguyen Thanh Thuy, Ca Nguyen Thuy Nha, Thomas Pouplin, Jeremy Farrar, Guy E. Thwaitesa and Hien Tran Tinh (2016). An HPLC method with diode array detector for the simultaneous quantification of chloroquin and desethylchloroquine in plasma and whole blood samples fromPlasmodium vivaxpatients in Vietnam, using quinine as an internal standard.Biomed. Chromatogr. 2016; 30: 1104?1111

86.Vijaykadga S, Rojanawatsivej C, Congpoung Ket al.,(2004). Assessment of therapeutic efficacy for vivax in Thailand.Southeast Asian J Trop Med public Health,2004; 35(3):566-9.

87.Vinetz JMet al.,(2006). Emerging chloroquin-resistantPlasmodium vivax(benign tertian) malaria: the need for alternative drug treatment.Clin Infect Dis2006 Apr 15;42(8):1073-4.

88.Nicholas J White (2010). Determinants of relapse periodicity inPlasmodium vivaxmalaria.Malaria Journal2011, 10:297.

89.USAID (2016).Manual for quantificationof malaria commodities rapid diagnostic tests and artemisinin-based combination therapy for first-line treatment ofPlasmodium falciparum..

90.Vinod P. Sharma, Vas Dev, Sobhan Phookan (2015). NeglectedPlasmodium vivaxmalaria in northeastern States of India.Indian J med Res141:546-555

91.White N.et al.,(2011). Determinants of relapse periodicity inPlasmodium vivaxmalaria. Malaria Journal 2011, 10:297

92.Michael T.White,GeorgeShirreff,StephanKarl (2017).Variation in relapse frequency and the transmission potential ofPlasmodium vivaxmalaria.Proc. R. Soc. B283:20160048.

93.Nicholas J. White, Tran T. Duong, Chirapong Uthaisin (2016). Antimalarial activity of KAF156 in falciparum and vivax malaria.N Engl J Med2016;375:1152-60.

94.WHO (2008). Methods and techniques for clinical trials o­n antimalarial drug efficacy: genotyping to identify parasite populations.

95.WHO (2009). Methods for surveillance of antimalarial drug efficacy.

96.WHO (2009). Parasitological confirmation of malaria diagnosis.

97.WHO (2010). Global report antimalarial drugs efficacy & drugs resistance

98.WHO (2011). Methods and technique for assessing exposure to antimalarial drugs in clinical field studies. Informal consultation organized by the WHO with the technical supports of the world wide antimalarial resistance network.

99.WHO (2012). ICH - GCP Guidelines for Clinical Trials

100.WHO (2012). WHO urges action as drug-resistant malaria spreads.

101.WHO (2012). Update WHO policy recommendation, Single dose primaquine as a gametocytocide inPlasmodium falciparummalaria

102.WHO (2013). Emergency response to artemisinin resistance in the greater Mekong subregion, Regional framework for action 2013-2015

103.WHO (2013). Case management: Guide for tutors, Traning module for malaria control.

104.WHO (2013).Updated WHO Policy Recommendation:Single dose primaquin as a gametocytocide inPlasmodium falciparummalaria

105.WHO (2013), Management of severe malaria: A practical hanbook

106.WHO (2013) Malaria Policy Advisory Committee to the WHO: Conclusions and recommendations of March 2013 meeting, Malaria Policy Advisory Committee and Secretariat,Malaria Journal2013, 12:213

107.WHO (2015). Guidelines for the treatment of malaria, third edition.

108.WHO (2015). A WHO external quality assurance scheme for malaria nucleic acid amplification testing,GlobalMalariaProgramme - Meeting report.

109.WHO (2015).Control and Elimination ofPlasmodium vivaxmalaria. A technical brief

110.WHO (2015). Confronting ofPlasmodium vivaxmalaria.

111.WHO (2016). World malaria report 2015.

112.WHO (2016).Testing for G6PD deficiency for safe use of primaquine in radical cure ofP. vivaxandP. ovalemalaria,Policy brief

113.WHO (2016). World malaria report 2016.

114.WHO (2016). WHO?s emergency response to artemisinin resistance, sept.2016

115.WHO (2016). Methods manual for laboratory quality control. Testing of malaria rapid diagnostic tests.

116.S. K. Wijesekera, R. Carter, Rathnayakaet al.,(1996). A malaria parasite toxin associated withPlasmodium vivaxparoxysms.Clin Exp Immunol1996;104:221-227

117.Yehenew A Ebstie1, Solomon M Abay, Wondmagegn T Tadesse (2016). Tafenoquine and its potential in the treatment and relapse prevention ofPlasmodium vivaxmalaria: the evidence to date.Drug Design, Development and Therapy, Open Access,dx.doi.org/10.2147/DDDT.S61443

118.Yeom JS,Jun G,Kim JY,Lee WJ,Shin EHet al.,(2012). Status ofPlasmodium vivaxmalaria in the republic of Korea, 2008-2009: decrease followed by resurgence.Trans R Soc Trop Med Hyg.;106(7):429-36.

119.Yonne F Chehuan, Monica RF Costa, Jacqueline S Costa (2013).In vitrochloroquine resistance forPlasmodium vivaxisolates from the Western Brazilian Amazon. Malaria Journal 2013, 12:226.